Login to Your Account



Financings Roundup

Tygacil by the Tail? Tetraphase IPO: $86M for New Antibiotics

By Randy Osborne
Staff Writer

Wednesday, February 13, 2013
Looking to bolster its planned Phase III trial with TP-434 (eravacycline) for complicated intra-abdominal infections, Tetraphase Pharmaceuticals Inc. filed for an initial public offering (IPO) that would raise up to $86.2 million, though neither the targeted number of shares nor the price of each was disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription